Dataset Information


Humanized mouse model of glucose 6-phosphate dehydrogenase deficiency for in vivo assessment of hemolytic toxicity.

ABSTRACT: Individuals with glucose 6-phosphate dehydrogenase (G6PD) deficiency are at risk for the development of hemolytic anemia when given 8-aminoquinolines (8-AQs), an important class of antimalarial/antiinfective therapeutics. However, there is no suitable animal model that can predict the clinical hemolytic potential of drugs. We developed and validated a human (hu)RBC-SCID mouse model by giving nonobese diabetic/SCID mice daily transfusions of huRBCs from G6PD-deficient donors. Treatment of SCID mice engrafted with G6PD-deficient huRBCs with primaquine, an 8-AQ, resulted in a dose-dependent selective loss of huRBCs. To validate the specificity of this model, we tested known nonhemolytic antimalarial drugs: mefloquine, chloroquine, doxycycline, and pyrimethamine. No significant loss of G6PD-deficient huRBCs was observed. Treatment with drugs known to cause hemolytic toxicity (pamaquine, sitamaquine, tafenoquine, and dapsone) resulted in loss of G6PD-deficient huRBCs comparable to primaquine. This mouse model provides an important tool to test drugs for their potential to cause hemolytic toxicity in G6PD-deficient populations.

SUBMITTER: Rochford R 

PROVIDER: S-EPMC3808620 | BioStudies | 2013-01-01

SECONDARY ACCESSION(S): 10.1073/pnas.1310402110

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5590573 | BioStudies
2018-01-01 | S-EPMC5931686 | BioStudies
2020-01-01 | S-EPMC7356471 | BioStudies
2018-01-01 | S-EPMC5928732 | BioStudies
2019-01-01 | S-EPMC6657225 | BioStudies
2014-01-01 | S-EPMC4136050 | BioStudies
2017-01-01 | S-EPMC5460895 | BioStudies
2019-01-01 | S-EPMC6411314 | BioStudies
2015-01-01 | S-EPMC4361223 | BioStudies
2017-01-01 | S-EPMC5575121 | BioStudies